Results 41 to 50 of about 6,275 (172)

A fully recombinant human IgG1 Fc multimer (GL-2045) inhibits complement-mediated cytotoxicity and induces iC3b

Blood Advances, 2017
: GL-2045 is a recombinant human immunoglobulin G1 (IgG1)–based Fc multimer designed to recapitulate the anti-inflammatory activities of intravenous immunoglobulin (IVIG) on the innate and adaptive immune responses. We used functional in vitro studies to
Hua Zhou, Henrik Olsen, Edward So, Emmanuel Mérigeon, Denis Rybin, Jane Owens, Gregory LaRosa, David S. Block, Scott E. Strome, Xiaoyu Zhang   +9 more
doaj   +1 more source

The interaction between circulating complement proteins and cutaneous microvascular endothelial cells in the development of childhood Henoch-Schönlein Purpura. [PDF]

PLoS ONE, 2015
In addition to IgA, the deposition of complement (C)3 in dermal vessels is commonly found in Henoch-Schönlein purpura (HSP). The aim of this study is to elucidate the role of circulating complement proteins in the pathogenesis of childhood HSP.Plasma ...
Yao-Hsu Yang, I-Jung Tsai, Chun-Jung Chang, Ya-Hui Chuang, Hui-Yao Hsu, Bor-Luen Chiang   +5 more
doaj   +1 more source

Subunits of C1Q Are Associated With the Progression of Intermittent Claudication to Chronic Limb-Threatening Ischemia

Frontiers in Cardiovascular Medicine, 2022
BackgroundThe pathophysiological mechanisms of intermittent claudication (IC) progression to chronic limb-threatening ischemia (CLTI) are still vague and which of patients with IC will become CLTI are unknown.
Ziping Yao, Bihui Zhang, Guochen Niu, Ziguang Yan, Xiaoqiang Tong, Yinghua Zou, Min Yang   +6 more
doaj   +1 more source

Serum Proteomic Signatures of Rheumatoid Arthritis Risk and Response: Analysis of a Rheumatoid Arthritis Interception Trial

Arthritis &Rheumatology, EarlyView.
Objective Our study objective was to identify serum protein signatures associated with progression to rheumatoid arthritis (RA) and response to abatacept in at‐risk individuals. Methods A total of 440 serum samples from 118 APIPPRA (Arthritis Prevention In the Preclinical Phase of RA with Abatacept) study participants were selected from baseline to RA ...
Marianna Jasenecova, Carl Coyle, Alina Mihalovits, Sarah Ryan, Elizabeth Pook, Esperanza Perucha, Gabrielle Harker, Melody Chin, Sam Norton, Andrew P. Cope   +9 more
wiley   +1 more source

Navigating adverse immunostimulation: A practical guide for clinical researchers

British Journal of Clinical Pharmacology, EarlyView.
Problem Setting As drug development moves towards more complex products, early clinical development programmes are increasingly hampered by unwanted and/or unexpected activation of the immune system (adverse immune stimulation, AIS). Solution At the Centre for Human Drug Research, we have introduced standardized procedures to make AIS manageable, while
Juliette A. van den Noort, Anouk C. Meijs, Naomi B. Klarenbeek, Matthijs Moerland   +3 more
wiley   +1 more source

Adverse immunostimulation in early phase clinical trials: Key findings and recommendations based on the investigator's clinical experience

British Journal of Clinical Pharmacology, EarlyView.
Problem setting The emergence of therapeutic proteins has coincided with an increase of acute adverse immunostimulation (AIS). AIS has occured in clinical trials despite compliance with regulatory guidelines on preclinical evaluation and its incidence is anticipated to increase even further.
Juliette A. van den Noort, Marella C. E. van Ruissen, Lisanne C. A. Smidt, Naomi B. Klarenbeek, Philip H. K. Kremer, Manon A. A. Jansen, Jacobus Burggraaf, Joop M. A. van Gerven, Matthijs Moerland   +8 more
wiley   +1 more source

Complement activation and regulation in preeclamptic placenta

Frontiers in Immunology, 2014
Preeclampsia (PE) is a common disorder of pregnancy originating in the placenta. We examined whether excessive activation or poor regulation of the complement system at the maternal-fetal interface could contribute to the development of PE.
A. Inkeri eLokki, A. Inkeri eLokki, A. Inkeri eLokki, Jenni eHeikkinen-Eloranta, Jenni eHeikkinen-Eloranta, Hanna eJarva, Hanna eJarva, Hanna eJarva, Terhi eSaisto, Marja-Liisa eLokki, Hannele eLaivuori, Hannele eLaivuori, Seppo eMeri, Seppo eMeri, Seppo eMeri   +14 more
doaj   +1 more source

An Open‐Label Phase 1b Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of ANX005 in Patients with Huntington's Disease

Movement Disorders, EarlyView.
Complement activation is implicated in Huntington's disease; ANX005 is a potent inhibitor of component C1q. ANX005 exhibited a generally manageable safety profile with rapid reduction in C1q in the cerebrospinal fluid. Functional ability on composite Unified Huntington's Disease Rating Scale and total functional capacity was maintained, with potential ...
Rajeev Kumar, Pinky Agarwal, Karen Anderson, Daniel Claassen, Marissa Dean, Andrew Duker, Burton Scott, Benjamin Hoehn, Ann Mongan, Ping Lin, Ellen Cahir‐McFarland, Lori Taylor, Glenn Morrison, Ted Yednock, Sanjay Keswani, Henk‐Andre Kroon   +15 more
wiley   +1 more source

Unexpected Dual Function of Plant YUCCA Enzymes Links Chlorophyll Catabolism to Auxin Homeostasis

Angewandte Chemie, Volume 138, Issue 9, 23 February 2026.
YUCCA enzymes are well known to catalyze the main step of auxin biosynthesis in plants. Here, a hitherto undescribed dual function was discovered, revealing that some YUCCAs also act in chlorophyll degradation. In vitro feedback regulation furthermore suggests a link between chlorophyll degradation and hormone homeostasis and a physiological role of ...
Sina Rütschlin, Lei Zhang, Cornelia A. Karg, Michael Zwerger, Johanna M. Gostner, Simone Moser, Robin Teufel   +6 more
wiley   +2 more sources

Complement C4-A and Plasminogen as Potential Biomarkers for Prediction of Papillary Thyroid Carcinoma

Frontiers in Endocrinology, 2021
BackgroundEarly diagnosis and therapy of papillary thyroid carcinoma (PTC) is essential for reducing recurrence and improving the long-term survival. In this study, we aimed to investigate the proteome profile of plasma and screen unique proteins which ...
Yichao Wang, Yichao Wang, Shengliang Zhou, Shengliang Zhou, Shengliang Zhou, Dun Wang, Dun Wang, Dun Wang, Tao Wei, Tao Wei, Jingqiang Zhu, Jingqiang Zhu, Zhihui Li   +12 more
doaj   +1 more source